<DOC>
	<DOCNO>NCT00037154</DOCNO>
	<brief_summary>The purpose study test whether extract saw palmetto plant effective relieving symptom Benign Prostatic Hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Saw Palmetto Extract Benign Prostatic Hyperplasia</brief_title>
	<detailed_description>This proposal describe double-blind , placebo-controlled randomized clinical trial effect saw palmetto extract symptom , objective parameter disease severity , quality life men moderate-to-severe benign prostatic hyperplasia . BPH , one common morbid medical condition middle-aged elderly men , generally treat alpha-adrenergic blocking agent , finasteride , surgical intervention , specific therapy ( `` watchful waiting '' ) . In past several year , however , many patient begin self-medicate extract saw palmetto plant ( Serenoa repens ) , medicinal herb grown southeastern United States . Saw palmetto become fifth lead medicinal herb consume U.S. consider first-line therapy BPH several Western European country . Several small study suggest saw palmetto may clinical benefit , methodologic quality prior study poor . Very side effect herb observe , study conduct three month . We propose conduct high-quality clinical trial saw palmetto , careful attention methodologic deficiency prior study . After single-blind placebo run-in period , 224 patient mode moderate-to-severe BPH ( American Urological Association Symptom Index score great equal 8 ) objective measurement urinary obstruction , randomize receive either 160mg BID herbal extract identical placebo . Patients discontinue medical therapy BPH prior enrollment participant undergo trans-rectal ultrasound examination baseline closeout . Participants trial see 3-month interval total one-year follow-up . Outcome measurement include change AUASI score ( primary outcome measurement ) , peak urinary flow rate , post-void residual urine volume , BPH Impact Index , Olmstead County Study Questionnaire BPH-specific symptom quality life , Short-Form 36 ( generic health status instrument ) . Numerous laboratory parameter measure interval throughout trial symptomatic side effect assess .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Permixon</mesh_term>
	<criteria>Eligibility Criteria : Participants must men , age 50 year old moderatetosevere BPH . Participants must history prostate cancer , prior surgery prostate , kidney failure , take furosemide ( Lasix ) , warfarin ( Coumadin ) , hormone medication . Individuals take medicine BPH must stop one month ( prazosin , terazosin ( Hytrin ) , doxazosin ( Cardura ) , tamsulosin ( Flomax ) ) six month ( saw palmetto , finasteride ( Proscar Rogaine ) ) prior enter study .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Herbal Therapies</keyword>
	<keyword>Complementary Alternative Medicine</keyword>
	<keyword>Men 's Health</keyword>
</DOC>